Spots Global Cancer Trial Database for metastatic
Every month we try and update this database with for metastatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | NCT04300790 | Breast Cancer | Alpelisib Metformin Fulvestrant Letrozole Exemestane Vildagliptin Tamoxifen | 18 Years - | MedSIR | |
| SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | NCT00270413 | Metastatic Brea... | SU11248 | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC | NCT03791398 | Metastatic Colo... | Dose level 1 ON... Dose level 2 ON... Dose level 3 ON... | 18 Years - | Brown University | |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium | NCT03761901 | Carcinoma, Non-... | 1L treatment 2L Treatment 3L treatment | 18 Years - | AstraZeneca | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. | NCT06086340 | Breast Cancer | Palbociclib Aromatase Inhib... | 65 Years - | Pfizer | |
| A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | NCT02623127 | Thymic Carcinom... | Sunitinib | 20 Years - | Seoul National University Hospital | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | NCT02048384 | Metastatic Panc... | metformin alone... metformin (Arm ... rapamycin (Arm ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | NCT01009515 | Melanoma | Paclitaxel, car... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | NCT01189929 | Pancreatic Canc... | Demcizumab Abraxane® Gemcitabine | 21 Years - | Mereo BioPharma | |
| Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | NCT01233375 | Metastatic Panc... | CO-1.01 | 18 Years - | Clovis Oncology, Inc. | |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | NCT01846429 | Tumor Cancer Pain Malignant Solid... Unresectable Ma... Hematologic Mal... Multiple Myelom... Lymphoma Neoplasm Metast... | Sodium Bicarbon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC | NCT00378404 | Non-Small Cell ... | Docetaxel Radiation | 18 Years - | University of Kentucky | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | NCT00523640 | Carcinoma, Rena... | combination of ... | 18 Years - | University of Chicago | |
| Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC | NCT00313859 | Colorectal Canc... Metastasis | simvastatin | 18 Years - | Samsung Medical Center | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma | NCT04990037 | Metastatic Panc... | CAN04 FOLFIRINOX | 18 Years - | Cantargia AB | |
| A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | NCT00744562 | Solid Tumors | OMP-21M18 | 21 Years - | Mereo BioPharma | |
| Cabozantinib for Metastatic Triple Negative BrCa | NCT01738438 | Breast Cancer | Cabozantinib | 18 Years - | Dana-Farber Cancer Institute | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent | NCT00836745 | Renal Cell Carc... | Non Interventio... | 18 Years - 75 Years | Pfizer | |
| Gallium-68 Citrate PET Used in Prostate Cancer | NCT02391025 | Prostatic Neopl... | Gallium-68 citr... Positron Emissi... | 18 Years - | University of California, San Francisco | |
| Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma | NCT02689167 | Kidney Neoplasm... Metastatic Rena... | Sunitinib | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | NCT01583543 | Ewing's Sarcoma | Olaparib | 18 Years - | Massachusetts General Hospital | |
| Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma | NCT03585673 | Esophagus Squam... Metastatic Canc... | Docetaxel-PM Oxaliplatin | 18 Years - | Dong-A University Hospital | |
| Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer | NCT02129556 | Metastatic Brea... | MK-3475 | 18 Years - | ETOP IBCSG Partners Foundation | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Safety and Efficacy of Cryoablation for Metastatic Lung Tumors | NCT01307501 | Metastatic Lung... | Cryoablation | 18 Years - | Boston Scientific Corporation | |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| CRLX101 Plus Bevacizumab in Advanced RCC | NCT01625936 | Renal Cell Carc... | CRLX101 (Cerule... Bevacizumab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | NCT00449280 | Advanced Solid ... | Sorafenib Rapamycin Rapamycin | 18 Years - | University of Chicago | |
| Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | NCT00812240 | Gastrointestina... | Masitinib Imatinib | 18 Years - | AB Science | |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies | NCT04465487 | Squamous Cell C... | REGN6569 Cemiplimab | 18 Years - | Regeneron Pharmaceuticals | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | NCT04247256 | Metastatic Colo... | FOLFIRI Protoco... SCO-101 | 18 Years - | Scandion Oncology A/S | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | NCT01161186 | Pancreatic Neop... Pancreatic Canc... Adenocarcinoma | nab-paclitaxel,... | 18 Years - | University of California, San Francisco | |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | NCT02917993 | Lung Cancer | Itacitinib Osimertinib | 18 Years - | Incyte Corporation | |
| A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | NCT02860546 | Refractory Meta... | TAS-102 nivolumab | 18 Years - | Taiho Oncology, Inc. | |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer | NCT04507698 | Prostate Cancer | Intensive Exerc... | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | |
| QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | NCT03027128 | Solid Tumor | haNK™ for Infus... | 18 Years - | ImmunityBio, Inc. | |
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) | NCT04752358 | Esophageal Canc... Esophagogastric... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | NCT00100685 | Renal Cell Carc... Metastases | Volociximab (an... | 18 Years - | Abbott | |
| TroVax Renal Immunotherapy Survival Trial | NCT00397345 | Clear Cell Rena... | Trovax Placebo Standard of car... | 18 Years - | Oxford BioMedica | |
| Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | NCT01879085 | Sarcoma | Docetaxel Gemcitabine Vorinostat Pegfilgrastim | 18 Years - | University of Pittsburgh | |
| AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. | NCT02102165 | Metastatic Brea... | metastatic lesi... | 18 Years - | Breast International Group | |
| Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | NCT02962804 | Carcinoma, Rena... | Nivolumab Radiation | 18 Years - | University of Kansas Medical Center | |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | NCT02124707 | Head and Neck C... Squamous Cell C... | Cetuximab Paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients | NCT03436056 | Metastatic Non-... | Stereotactic Bo... Stereotactic Bo... Stereotactic Bo... Pembrolizumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients | NCT03795012 | Breast Cancer | Eribulin | 18 Years - | MedSIR | |
| Pazopanib, Docetaxel, Prednisone Prostate | NCT01385228 | Prostate Cancer | Pazopanib Docetaxel Pazopanib Prednisone Pegfilgrastim | 18 Years - | Duke University | |
| Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | NCT00176280 | Renal Cell Carc... | Leukine Dexamethasone | 18 Years - | University of Kentucky | |
| Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer | NCT05219435 | Urothelial Canc... | Nivolumab Ipilimumab | 18 Years - | Spanish Oncology Genito-Urinary Group | |
| A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | NCT02259582 | Nonsquamous Non... | Pemetrexed Carboplatin demcizumab | 21 Years - | Mereo BioPharma | |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811 | Vaginal Cancer Cervical Cancer Anal Cancer Penile Cancer Oropharyngeal C... | Fludarabine Cyclophosphamid... E6 TCR Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer | NCT02964078 | Kidney Cancer | Pembrolizumab Interleukin-2 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| BKM120 For Triple Negative Breast Cancer | NCT01790932 | Breast Cancer | BKM120 | 18 Years - | Dana-Farber Cancer Institute | |
| A Study in Advanced Cancer | NCT01226485 | Advanced Cancer | Taladegib | 18 Years - | Eli Lilly and Company | |
| TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | NCT04887506 | Metastatic Cast... Metastatic Cast... Metastatic Pros... | TAVT-45 Zytiga Prednisone | 18 Years - | Tavanta Therapeutics | |
| Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00090727 | Solid Malignanc... Non-Hodgkin's L... | AQ4N | 18 Years - | Novacea | |
| Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer | NCT01492543 | Breast Cancer | Tegafur Gimerac... | 18 Years - 75 Years | ChineseAMS | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | NCT01495247 | Inoperable Loca... Metastatic Brea... | BEZ235 Paclitaxel | 18 Years - | Novartis | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | NCT00661830 | Adenocarcinoma | Gemcitabine Placebo Sorafenib | 18 Years - | Johannes Gutenberg University Mainz | |
| Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00323882 | Prostate Cancer Neoplasm Metast... | MDX-010 | 18 Years - | Bristol-Myers Squibb | |
| Melanoma Biomarker Study | NCT00348088 | Metastatic Mela... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ||
| A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium | NCT00035061 | Urologic Neopla... Metastases, Neo... | pemetrexed | 18 Years - | Eli Lilly and Company | |
| PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY | NCT03423199 | Breast Neoplasm... | Palbociclib Placebo Tamoxifen Goserelin | 18 Years - | National Cancer Center, Japan | |
| Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00356122 | Non-Small Cell ... | Docetaxel Oxaliplatin Bevacizumab | 18 Years - | Sanofi | |
| Cetuximab + Gemox in Biliary Tract Cancer | NCT01216345 | Unresectable Locally Advance... Metastatic | Cetuximab + Gem... | 18 Years - | Association of Research on the Biology of Liver Tumors | |
| Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | NCT01139346 | Advanced Solid ... | darinaparsin | 18 Years - | Alaunos Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
